{"id":816,"date":"2026-03-30T06:59:35","date_gmt":"2026-03-30T06:59:35","guid":{"rendered":"https:\/\/batnajms.net\/?p=816"},"modified":"2026-03-30T06:59:51","modified_gmt":"2026-03-30T06:59:51","slug":"bouaoua","status":"publish","type":"post","link":"https:\/\/batnajms.net\/index.php\/2026\/03\/30\/bouaoua\/","title":{"rendered":"Population pharmacokinetics of amikacin in Algeria: implications for dosing optimization and individualized therapy"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\" id=\"block-c2f138d4-0208-4b99-af09-93c83eb26d35\"><strong><a href=\"https:\/\/batnajms.net\/wp-content\/uploads\/Archives\/2026\/04\/BJMS_Bouaoua.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Fulltext\u00a0<\/strong><\/a>(PDF)<\/strong><\/h3>\n\n\n\n<p><strong>DOI<\/strong>: 10.48087\/BJMS.2026.130408<\/p>\n\n\n\n<p><strong>Authors:<\/strong>\u00a0Fatima Zohra BOUAOUA\u00b9, <a>Houari TOUMI\u00b2<\/a>, Karim BOULESBIAAT\u00b3,Habiba FETATI\u00b2, Hocine GACEM\u00b3, Farida BOUCHNAK\u2074, Abdelrahmane ABDAOUI\u00b2, Zahia HAZMOUNE\u00b9, Badis FOUGHALI\u00b9, Soumia BOUDJEMAA\u00b3, Sabah BENBOUDIAF\u00b9, Fatma Zohra BOUDIA\u00b2, Rafika LAICHE\u00b3, Faiza BOUCHALA\u2075, Kamel MANSOURI\u2074<\/p>\n\n\n\n<p><strong>Affiliations:<\/strong>\u00a01- Facult\u00e9 de m\u00e9decine, Universit\u00e9 Constantine 3 \u2013 Salah Boubnider, Alg\u00e9rie. 2- Facult\u00e9 de m\u00e9decine, Universit\u00e9 d\u2019Oran 1 Ahmed Ben Bella, Alg\u00e9rie. 3- Facult\u00e9 de m\u00e9decine, Universit\u00e9 de Batna 2 \u2013 Mostefa Ben Boula\u00efd, <a>Alg\u00e9rie<\/a>. 4- Facult\u00e9 de m\u00e9decine, Universit\u00e9 d\u2019Alger 1 Benyoucef Benkhedda, Alg\u00e9rie. 5- Facult\u00e9 de m\u00e9decine, Universit\u00e9 Ferhat Abbas S\u00e9tif 1, Alg\u00e9rie.<\/p>\n\n\n\n<p><strong>Abstract<\/strong><\/p>\n\n\n\n<p><strong>Introduction:<\/strong> Amikacin is a bactericidal aminoglycoside widely used in the treatment of severe infections caused by multidrug-resistant Gram-negative bacilli. Its clinical use is limited by significant interindividual pharmacokinetic variability and the risk of nephrotoxicity and ototoxicity. Its narrow therapeutic window complicates dose individualization, making it challenging to optimize efficacy while minimizing toxicity. The objective of this study was to develop an initial dose adjustment approach for amikacin based on a population pharmacokinetic (PKpop) model integrated with therapeutic drug monitoring (TDM), in order to propose optimized dosing regimens. <strong>Materials and Methods:<\/strong> A retrospective and prospective study was conducted in hospitalized patients receiving amikacin. Plasma concentrations were measured using an immunoenzymatic method and modeled using a nonlinear mixed-effects approach. Covariates assessed included body weight and creatinine clearance. Monte Carlo simulations were performed on 1,000 virtual patients to evaluate the probability of target attainment for minimum (Cmin) and maximum (Cmax) plasma concentrations. <strong>Results:<\/strong> Among the 50 patients with normal renal function included (MDRD: 115.8 \u00b1 13 mL\/min), a one-compartment model was selected, estimating a population volume of distribution (Vpop) of 23.3 L, 70.8 L, and 21.5 L, and a population clearance (Clpop) of 2.4 L\/h, 6.5 L\/h, and 2.7 L\/h for children, adults, and elderly patients, respectively. Relative standard errors were low, indicating good model precision and stability. Simulations demonstrated that optimal doses to achieve target concentrations varied by age group: 50 mg\/kg every 24 hours for adults, and 20 mg\/kg every 36\u201348 hours for children and elderly patients. <strong>Discussion:<\/strong> These findings suggest that standard dosing regimens are often insufficient to meet efficacy and safety targets. Integrating population pharmacokinetics with therapeutic drug monitoring enables dose individualization, improves treatment efficacy, and reduces the risk of toxicity.<\/p>\n\n\n\n<p><strong>_____________________________________________________________<\/strong><strong><\/strong><\/p>\n\n\n\n<p><strong>Keywords<\/strong><strong>: <\/strong>Amikacin, population pharmacokinetics, therapeutic drug monitoring, simulation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fulltext\u00a0(PDF) DOI: 10.48087\/BJMS.2026.130408 Authors:\u00a0Fatima Zohra BOUAOUA\u00b9, Houari TOUMI\u00b2, Karim BOULESBIAAT\u00b3,Habiba FETATI\u00b2, Hocine GACEM\u00b3, Farida BOUCHNAK\u2074, Abdelrahmane ABDAOUI\u00b2, Zahia HAZMOUNE\u00b9, Badis FOUGHALI\u00b9, Soumia BOUDJEMAA\u00b3, Sabah BENBOUDIAF\u00b9, Fatma Zohra BOUDIA\u00b2, Rafika LAICHE\u00b3, Faiza BOUCHALA\u2075, Kamel MANSOURI\u2074 Affiliations:\u00a01- Facult\u00e9 de m\u00e9decine, Universit\u00e9 Constantine 3 \u2013 Salah Boubnider, Alg\u00e9rie. 2- Facult\u00e9 de m\u00e9decine, Universit\u00e9 d\u2019Oran 1 Ahmed Ben Bella, &hellip; <a href=\"https:\/\/batnajms.net\/index.php\/2026\/03\/30\/bouaoua\/\" class=\"more-link\">Continuer la lecture de <span class=\"screen-reader-text\">Population pharmacokinetics of amikacin in Algeria: implications for dosing optimization and individualized therapy<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-816","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/posts\/816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/comments?post=816"}],"version-history":[{"count":1,"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/posts\/816\/revisions"}],"predecessor-version":[{"id":817,"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/posts\/816\/revisions\/817"}],"wp:attachment":[{"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/media?parent=816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/categories?post=816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/batnajms.net\/index.php\/wp-json\/wp\/v2\/tags?post=816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}